11 filings
8-K
SLRN
Acelyrin Inc
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
8-K
SLRN
Acelyrin Inc
20 Mar 24
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile
7:04am
8-K
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
SLRN
Acelyrin Inc
20 Dec 23
Departure of Directors or Certain Officers
4:38pm
8-K
SLRN
Acelyrin Inc
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
fqrwfxxpe0rynk790b
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
o3zk591xyu54gjtf fxg
21 Aug 23
Departure of Directors or Certain Officers
4:03pm
8-K
h6jk6wdb4a8s
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
tffopk
2 Aug 23
Departure of Directors or Certain Officers
5:05pm
8-K
rcfc7 u5wj2d
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
m9i3b5ylhacpfx
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
- Prev
- 1
- Next